|Other names||Moricizine (USAN US)|
|AHFS/Drugs.com||Consumer Drug Information|
|Elimination half-life||3–4 hours (healthy volunteers), 6–13 hours (cardiac disease)|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||427.518 g/mol g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Moracizine or moricizine, sold under the trade name Ethmozine, is an antiarrhythmic of class IC. It was used for the prophylaxis and treatment of serious and life-threatening ventricular arrhythmias, but was withdrawn in 2007 for commercial reasons.
Moracizine, a phenothiazine derivative, undergoes extensive first-pass metabolism and is also extensively metabolized after it has entered the circulation. It may have pharmacologically active metabolites. A clinical study has shown that moracizine is slightly less effective than encainide or flecainide in suppressing ventricular premature depolarizations. Compared with disopyramide and quinidine, moracizine was equally or more effective in suppressing premature ventricular contractions, couplets, and nonsustained ventricular tachycardia.
In the Cardiac Arrhythmia Suppression Trial (CAST), a large study testing the influence of antiarrhythmics on mortality, showed a statistically non-significant increase of mortality from 5.4 to 7.2% under moracizine. This is in line with other class IC antiarrhythmics.
|This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.|